Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The pathogenic bacterium cell wall is a complex, mesh-like structure essential for bacterial survival, composed mainly of peptidoglycan (also called murein), which forms a rigid layer around the plasma membrane[1][4][8]. The cell wall maintains cell shape, structural integrity, and protects against osmotic pressure[1][2][6]. It is the primary point of vulnerability for many antibiotics, especially in clinically relevant pathogens[4][6]. - In Gram-positive bacteria, the cell wall is thick and consists predominantly of peptidoglycan, along with teichoic acids that contribute to rigidity, ion homeostasis, and cell division[2][3][5]. - In Gram-negative bacteria, the cell wall is thinner, with a single or few layers of peptidoglycan surrounded by an outer membrane containing lipopolysaccharide (LPS, a potent endotoxin), proteins, and lipoproteins[2][5][6]. - Other structural decorations include wall teichoic acids and capsule polysaccharides (Gram-positive) or periplasmic space and O-antigen (Gram-negative)[2][4][5][6]. Because peptidoglycan is absent from eukaryotic cells, the bacterial cell wall is an excellent therapeutic target. Beta-lactam antibiotics (such as penicillins and cephalosporins) inhibit enzymes involved in peptidoglycan synthesis, causing cell death[6]. Drugs such as vancomycin, bacitracin, and fosfomycin act on other cell wall synthesis steps. Lysozyme, an enzyme found in human tears and secretions, also degrades peptidoglycan and serves as a natural defense[6]. Significant therapeutic challenges include the emergence of bacterial resistance due to various mechanisms (enzyme production, target modification, efflux), disruption of normal microbial flora, and the risk of massive endotoxin release (e.g., LPS) upon bacteriolysis[6]. While the phrase “Pathogenic bacteria cell wall” is somewhat imprecise (referring to a structural feature rather than a discrete molecular entity), the cell wall is recognized as a critical and druggable macromolecular complex in infectious disease pharmacology[4][6].
Inhibition of cell wall (peptidoglycan) biosynthesis, Disruption of cell wall crosslinking, Enzymatic degradation of peptidoglycan, Inhibition of lipid II translocation
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogenic bacterium cell wall.